Does Anthem Cover Prolia? A Complete Insurance Guide

What Is Prolia and Why Does Coverage Matter?

Prolia is a RANK-ligand inhibitor that reduces bone resorption and lowers fracture risk in postmenopausal women and men with osteoporosis. The FDA first approved denosumab in June 2010 for postmenopausal osteoporosis, and the indication has since expanded to include glucocorticoid-induced osteoporosis and bone loss in certain cancer patients [1]. At a list price near $1,400 per injection, a patient who stops treatment abruptly because of cost faces a documented rebound spike in vertebral fracture risk, a phenomenon described explicitly in Prolia's FDA prescribing information [2].

The FREEDOM trial (N=7,868) showed that denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over three years compared with placebo (P<0.001 for all three endpoints) [3]. Those numbers give prescribers strong clinical grounds when writing prior authorization letters to Anthem.

Coverage matters here more than it does for an oral generic. Prolia is never dispensed as a $10 tablet at a retail pharmacy. It either ships from a specialty pharmacy (requiring cold-chain handling) or is administered in a physician's office under the medical benefit. Each billing pathway has its own cost-sharing rules under Anthem plans.

How Anthem Categorizes Prolia: Medical Benefit vs. Pharmacy Benefit

Whether Prolia lands under your medical or pharmacy benefit is the single biggest factor in what you will pay. Anthem routes Prolia one of two ways depending on how the drug is administered and billed.

Medical benefit (buy-and-bill). When a physician purchases Prolia directly, administers it in the office, and bills Anthem with HCPCS code J0897 (denosumab 1 mg, so 60 units for a 60 mg dose), the claim is processed under your medical benefit [4]. In this scenario, the drug is subject to your medical deductible and outpatient coinsurance, often 10 to 30% after the deductible is met. For many Anthem PPO or HMO members, this is the lower out-of-pocket pathway once the deductible is satisfied.

Specialty pharmacy benefit. Some Anthem plans require or allow members to obtain Prolia through a preferred specialty pharmacy (often CuraScript, Accredo, or Anthem's own AcariaHealth). The drug then ships to the provider's office or directly to the patient, and the claim is processed as a specialty pharmacy prescription under the pharmacy benefit. Specialty tier cost-sharing can run $100, $300 per fill on higher-tier formularies.

Anthem's 2024 commercial formularies generally place denosumab on a specialty tier requiring prior authorization regardless of which benefit pathway processes the claim [5]. Always call the member services number on the back of your insurance card and ask two specific questions: (1) Is J0897 covered under my medical benefit? and (2) Is denosumab listed on my specialty pharmacy formulary?

Anthem Prior Authorization Criteria for Prolia

Prior authorization (PA) is required for nearly every Anthem plan covering Prolia. The clinical criteria Anthem publishes in its medical necessity guidelines are consistent with American Association of Clinical Endocrinology (AACE) and Endocrine Society recommendations for osteoporosis pharmacotherapy [6]. A prescriber who documents the following items has the strongest chance of first-pass approval.

Bone density documentation. Anthem typically requires a DEXA scan showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, OR a T-score at or below -1.0 with one or more clinical risk factors (prior fragility fracture, glucocorticoid use of 5 mg/day prednisone equivalent for 3+ months, or a FRAX 10-year hip fracture probability above 3%) [6].

Prior bisphosphonate trial or contraindication. Most Anthem commercial PA policies require a documented trial of at least 12 months with an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly are the most common), or documented evidence that bisphosphonates are contraindicated. Contraindications Anthem recognizes include severe renal impairment (eGFR <35 mL/min/1.73m²), esophageal motility disorders, and intolerance documented by a prescriber [7]. Anthem's medical necessity criteria also accept documented failure, defined as a new fracture or continued bone loss (T-score decrease of 0.5 or more) despite compliant bisphosphonate use.

Prescriber specialty. Anthem sometimes restricts Prolia PA approvals to rheumatologists, endocrinologists, or gynecologists, with primary care physicians needing to demonstrate osteoporosis management experience. Checking your specific plan's PA criteria before submission prevents delays.

Duration of approval. Initial PA approvals on most Anthem plans cover two injections (one full year). Reauthorization requires repeat DEXA or documentation of stable/improved bone density and ongoing clinical need.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) states in its 2022 Clinician's Guide: "Pharmacologic therapy is recommended for postmenopausal women and men age 50 and older presenting with hip or vertebral fractures, T-scores of -2.5 or below, or T-scores between -1.0 and -2.5 with a 10-year hip fracture probability of 3% or greater" [8]. Prescribers who quote this guideline language directly in PA letters routinely report faster approvals.

Step Therapy: Does Anthem Require Bisphosphonates First?

Step therapy is standard. Anthem's clinical policy bulletins for denosumab require that a member has tried and failed, or has a contraindication to, at least one first-line bisphosphonate before Prolia will be authorized [7]. Alendronate (Fosamax) remains the most commonly mandated first step because it is available generically at under $10 per month.

The clinical justification for bypassing step therapy is well-supported in the literature. A 2019 analysis published in the Journal of Bone and Mineral Research found that patients with eGFR <35 mL/min/1.73m² treated with bisphosphonates had significantly higher rates of adynamic bone disease compared with patients who received denosumab directly [9]. Providing this data point to Anthem's PA reviewers when requesting a step therapy waiver strengthens a contraindication argument for renal patients.

Glucocorticoid-induced osteoporosis is a separate case. American College of Rheumatology 2022 guidelines recommend bisphosphonates or anabolic agents as initial therapy, with denosumab as an alternative for patients who cannot tolerate oral bisphosphonates or who have renal impairment [10]. Anthem's criteria for glucocorticoid-induced osteoporosis tend to mirror these ACR guidelines, so citing the ACR document by name (DOI: 10.1002/art.42105) in a PA letter can expedite review.

How Much Will You Pay Out of Pocket With Anthem?

Cost-sharing varies significantly by plan type and deductible status. These figures represent typical ranges across Anthem's 2024 individual and employer-sponsored commercial plans.

Under the medical benefit, members with a $1,500 individual deductible who have already met it commonly pay 20% coinsurance on the allowed amount. Anthem's allowed amount for J0897 (60 mg denosumab) typically runs $900, $1,100 per injection under in-network contracts, meaning a 20% coinsurance produces a $180, $220 member payment per dose.

Under the pharmacy benefit at a specialty tier, a standard 30% specialty coinsurance on a $1,400 list price equals $420 per injection before any manufacturer coupon. This is why verifying which benefit pathway applies to your specific plan is worth a phone call before the first injection.

Amgen SupportPlus copay card. Amgen offers the SupportPlus program for commercially insured patients who do not have Medicare or Medicaid. Eligible members may pay as little as $0 per dose for up to 12 doses per year, with the card covering up to $3 to 500 in cost-sharing annually [11]. The card cannot be used by Medicare or Medicaid beneficiaries under federal anti-kickback rules.

Medicare Advantage through Anthem. Anthem Medicare Advantage plans (branded as Anthem Medicare Preferred or similar) cover Prolia under Part D (pharmacy) or Part B (medical). Under Part B, denosumab is covered when administered by a provider, with a standard 20% coinsurance after the Part B deductible ($240 in 2024) [12]. The Amgen copay card does not apply to Medicare.

What to Do If Anthem Denies Your Prolia Prior Authorization

Denials happen. Common denial reasons include: no documented DEXA scan in the file, bisphosphonate trial not appearing in the claims history because it was filled at a cash pharmacy, or a prescriber leaving a required field blank on the PA form.

The first step is requesting the specific denial reason in writing (called an Explanation of Benefits or EOB). Federal law under the ACA requires insurers to provide a written reason for every adverse benefit determination [13].

Level 1 appeal (internal). File a written appeal within 180 days of the denial date. Attach: the DEXA scan report with T-score, prescriber's letter citing FREEDOM trial fracture reduction data and the Bone Health and Osteoporosis Foundation guideline, documentation of bisphosphonate trial or contraindication, and any peer-reviewed literature supporting Prolia over continued bisphosphonate use for the specific clinical scenario. Studies in the Journal of Bone and Mineral Research show that internal appeals of specialty drug denials succeed at rates of 40 to 55% when accompanied by clinical literature [14].

Independent external review. If the internal appeal fails, request an external review through a state-certified Independent Review Organization (IRO). The ACA guarantees this right for most non-grandfathered plans [13]. External reviewers approved the appealed claim in approximately 59% of cases involving specialty osteoporosis drugs in 2022 CMS data [15].

Peer-to-peer review. Before filing a formal appeal, the prescribing physician may call Anthem's medical director for a peer-to-peer conversation. This informal step resolves many denials within 48 to 72 hours and avoids the longer formal appeal timeline.

Anthem Medicare Advantage vs. Commercial: Key Coverage Differences

Anthem's Medicare Advantage plans apply different formulary rules than its commercial plans. Understanding the distinction prevents surprises.

Under commercial Anthem plans, Prolia lands on the specialty tier of the pharmacy formulary or is billed under the medical benefit. The manufacturer coupon card is available. Step therapy waivers are attainable with documentation.

Under Anthem Medicare Advantage, Prolia is typically covered under Part B when physician-administered (HCPCS J0897), subject to the standard 20% Part B coinsurance after the annual deductible [12]. When dispensed through a Part D plan, denosumab appears on the specialty tier (Tier 5 on most Anthem Medicare formularies), with cost-sharing often running $100, $200 per fill depending on the plan's cost-sharing structure and whether the member is in the coverage gap. The Inflation Reduction Act capped Medicare Part D out-of-pocket costs at $2,000 annually starting in 2025, which benefits members requiring Prolia and other high-cost specialty drugs [16].

The core PA criteria under Medicare Advantage mirror CMS coverage policy: documented osteoporosis diagnosis (ICD-10 M81.0 for age-related osteoporosis) and a T-score at or below -2.5, or a prior fragility fracture [12].

How to Submit a Prolia Prior Authorization to Anthem

The prescriber's office bears most of the administrative burden here, but patients who understand the process can prompt their care team to submit complete documentation.

Anthem accepts PA requests through three channels: the Availity provider portal (Anthem's primary electronic prior authorization system), a dedicated fax line printed on the PA request form (downloadable from anthem.com for providers), and by phone through Anthem's pharmacy clinical team. Electronic submission through Availity returns decisions faster, typically within 1, 3 business days for non-urgent requests, compared with 5 to 14 days by fax [5].

The prescriber should include in the submission: a completed Anthem Prolia/Xgeva PA request form, the most recent DEXA scan report (within the past 24 months), ICD-10 diagnosis code, documentation of prior bisphosphonate use or contraindication, serum calcium and creatinine results if renal impairment is the step therapy waiver justification, and the clinical rationale tying the patient's fracture risk to the FREEDOM trial outcomes data [3].

Once approved, the authorization number must appear on the prescription or the physician's claim. A missing authorization number is the most common reason a technically-approved claim still gets rejected at the billing stage.

Prolia Alternatives Anthem Covers and When They Apply

When Prolia is denied or unaffordable, several alternatives exist on Anthem formularies with different cost and coverage profiles.

Alendronate (generic Fosamax) 70 mg weekly is Tier 1 on virtually all Anthem formularies, with a typical 30-day supply costing $0, $15. For patients without contraindications who have not yet tried a bisphosphonate, this is the standard first-line path that satisfies Anthem's step therapy requirement and may itself provide adequate fracture protection. A 2011 meta-analysis in the BMJ (N=26 trials) found that alendronate reduced vertebral fracture risk by approximately 45% and hip fracture risk by 38% in postmenopausal women with osteoporosis [17].

Zoledronic acid (Reclast) 5 mg IV annually is covered under the medical benefit on most Anthem plans. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in morphometric vertebral fractures at 3 years with zoledronic acid compared with placebo [18]. For patients who cannot tolerate oral bisphosphonates due to GI issues, this once-yearly IV option bypasses the GI tract and may satisfy step therapy requirements.

Romosozumab (Evenity) and teriparatide (Forteo) are anabolic agents with more complex Anthem PA criteria and higher costs. These are generally reserved for very high fracture risk patients or those who have failed or cannot tolerate antiresorptive therapy [6].